GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » Cyclically Adjusted Revenue per Share

CollPlant Biotechnologies (CollPlant Biotechnologies) Cyclically Adjusted Revenue per Share : $0.77 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

CollPlant Biotechnologies's adjusted revenue per share for the three months ended in Mar. 2024 was $0.009. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.77 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-08), CollPlant Biotechnologies's current stock price is $5.1299. CollPlant Biotechnologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.77. CollPlant Biotechnologies's Cyclically Adjusted PS Ratio of today is 6.66.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of CollPlant Biotechnologies was 8.61. The lowest was 6.28. And the median was 6.80.


CollPlant Biotechnologies Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for CollPlant Biotechnologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies Cyclically Adjusted Revenue per Share Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.78

CollPlant Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.81 0.78 0.77

Competitive Comparison of CollPlant Biotechnologies's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, CollPlant Biotechnologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Cyclically Adjusted PS Ratio falls into.



CollPlant Biotechnologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CollPlant Biotechnologies's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.009/131.7762*131.7762
=0.009

Current CPI (Mar. 2024) = 131.7762.

CollPlant Biotechnologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.001 102.862 0.001
201706 0.000 103.349 0.000
201709 0.001 104.136 0.001
201712 0.078 104.011 0.099
201803 0.001 105.290 0.001
201806 0.001 106.317 0.001
201809 0.049 106.507 0.061
201812 0.940 105.998 1.169
201903 0.127 107.251 0.156
201906 0.130 108.070 0.159
201909 0.146 108.329 0.178
201912 0.074 108.420 0.090
202003 0.091 108.902 0.110
202006 0.118 108.767 0.143
202009 0.419 109.815 0.503
202012 0.080 109.897 0.096
202103 1.263 111.754 1.489
202106 0.068 114.631 0.078
202109 0.013 115.734 0.015
202112 0.029 117.630 0.032
202203 0.006 121.301 0.007
202206 0.006 125.017 0.006
202209 0.010 125.227 0.011
202212 0.005 125.222 0.005
202303 0.038 127.348 0.039
202306 0.865 128.729 0.885
202309 0.004 129.860 0.004
202312 0.026 129.419 0.026
202403 0.009 131.776 0.009

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


CollPlant Biotechnologies  (NAS:CLGN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CollPlant Biotechnologies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.1299/0.77
=6.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of CollPlant Biotechnologies was 8.61. The lowest was 6.28. And the median was 6.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


CollPlant Biotechnologies Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies (CollPlant Biotechnologies) Business Description

Industry
Traded in Other Exchanges
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.

CollPlant Biotechnologies (CollPlant Biotechnologies) Headlines